ESR1 and breast cancer: Early BC patients [49] who completed at least 2 years of AI adjuvant treatment and experienced a documented relapse after the end of their treatment presented ESR1 mutations in approximately 30% of cases, and an increase in mutation allele frequency (MAF) was associated with clinical deterioration.